Literature DB >> 11820717

Soluble urokinase plasminogen activator receptor measurements: influence of sample handling.

R Riisbro1, I J Christensen, C Høgdall, N Brünner, E Høgdall.   

Abstract

AIM: The influence of sample handling on soluble urokinase plasminogen activator receptor (suPAR) concentrations in serum and EDTA plasma was studied in 16 healthy premenopausal women.
METHOD: Blood was collected in dry tubes and tubes containing EDTA and kept at 4 degrees C or 20 degrees C for 1, 3, 8, 24 or 72 hours before processing into serum or EDTA plasma. In addition, serum and EDTA plasma were frozen and thawed 1-8 times. All suPAR measurements were performed by ELISA.
RESULTS: No significant differences were found between serum or EDTA plasma suPAR concentrations when whole blood samples were kept for 1, 3, 8 or 24 hours. Significantly higher suPAR levels were found in samples kept for 72 hours at 20 degrees C compared to samples processed into serum or EDTA plasma after short-term storage for no more than 24 hours after collection. No significant differences were observed when whole blood was kept at 4 degrees C for up to 72 hours. Repeated freezing and thawing had no significant effect on the serum and EDTA plasma suPAR levels.
CONCLUSION: suPAR values in blood samples are dependent on the handling procedures of the samples. All samples of whole blood must be processed into EDTA plasma or serum within 24 hours if kept at 20 degrees C and within 72 hours if kept at 4 degrees C. However, repeated freezing/thawing cycles had no influence on suPAR values in the samples.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11820717     DOI: 10.1177/172460080101600402

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  25 in total

1.  Is there clinical value in measuring suPAR levels in FSGS?

Authors:  Sanja Sever; Howard Trachtman; Changli Wei; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-25       Impact factor: 8.237

2.  Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.

Authors:  Darcy K Weidemann; Alison G Abraham; Jennifer L Roem; Susan L Furth; Bradley A Warady
Journal:  Am J Kidney Dis       Date:  2020-01-24       Impact factor: 8.860

3.  Soluble Urokinase Receptor and Acute Kidney Injury.

Authors:  Salim S Hayek; David E Leaf; Ayman Samman Tahhan; Mohamad Raad; Shreyak Sharma; Sushrut S Waikar; Sanja Sever; Alex Camacho; Xuexiang Wang; Ranadheer R Dande; Nasrien E Ibrahim; Rebecca M Baron; Mehmet M Altintas; Changli Wei; David Sheikh-Hamad; Jenny S-C Pan; Michael W Holliday; James L Januzzi; Steven D Weisbord; Arshed A Quyyumi; Jochen Reiser
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

4.  Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.

Authors:  Burcin Özdirik; Martin Maibier; Maria Scherf; Jule Marie Nicklaus; Josephine Frohme; Tobias Puengel; Dirk Meyer Zum Büschenfelde; Frank Tacke; Tobias Mueller; Michael Sigal
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

5.  Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department.

Authors:  Ivo Casagranda; Chiara Vendramin; Tiziana Callegari; Matteo Vidali; Alessandra Calabresi; Giovanna Ferrandu; Gianfranco Cervellin; Mario Cavazza; Giuseppe Lippi; Isabella Zanotti; Sophie Negro; Andrea Rocchetti; Carlo Arfini
Journal:  Intern Emerg Med       Date:  2015-07-09       Impact factor: 3.397

6.  SuPAR and PAI-1 in critically ill, mechanically ventilated patients.

Authors:  Ville Jalkanen; Runkuan Yang; Rita Linko; Heini Huhtala; Marjatta Okkonen; Tero Varpula; Ville Pettilä; Jyrki Tenhunen
Journal:  Intensive Care Med       Date:  2012-10-26       Impact factor: 17.440

Review 7.  Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.

Authors:  Yara Backes; Koenraad F van der Sluijs; David P Mackie; Frank Tacke; Alexander Koch; Jyrki J Tenhunen; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2012-06-16       Impact factor: 17.440

8.  Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study.

Authors:  Thomas Huneck Haupt; Janne Petersen; Gertrude Ellekilde; Henrik Hedegaard Klausen; Christian Wandall Thorball; Jesper Eugen-Olsen; Ove Andersen
Journal:  Crit Care       Date:  2012-07-23       Impact factor: 9.097

9.  Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.

Authors:  Alexander Koch; Sebastian Voigt; Carsten Kruschinski; Edouard Sanson; Hanna Dückers; Andreas Horn; Eray Yagmur; Henning Zimmermann; Christian Trautwein; Frank Tacke
Journal:  Crit Care       Date:  2011-02-16       Impact factor: 9.097

10.  Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy.

Authors:  István Ivancsó; Gergely Toldi; Anikó Bohács; Noémi Eszes; Veronika Müller; János Rigó; Barna Vásárhelyi; György Losonczy; Lilla Tamási
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.